|
 Exparel is currently injected into the site of an operation to
manage pain after surgery and Pacira sought to use the drug as a
nerve numbing injection for cases where it is difficult to inject a
painkiller directly into the affected area.
Pacira said on Monday it would work with the FDA to secure the new
indication for Exparel, which will allow it to harness a wider range
of post-operative patients.
The drug combines a local anesthetic, bupivacaine, with the
company's DepoFoam technology, a drug delivery system that releases
the medicine over a period of time.
Exparel, approved in April 2012 for post-surgical pain, generated
$188.5 million of Pacira's nearly $197.6 million in revenue for the
year ended Dec. 31.
Last week, Pacira had said it expected Exparel sales to rise to
$310-$330 million in 2015, with about 10 percent of the projected
revenue coming from the expanded use of the drug.
[to top of second column] |
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Savio
D'Souza)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
